Bowen Disease of the Eyelid Successfully Treated with Imiquimod

Brannan, Paul A; Anderson, Heidi K.; Kersten, Robert C.; Kulwin, Dwight R.

doi:10.1097/01.iop.0000170421.07098.61

Cited by 31 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patel et al [6 ] conducted a randomized study to evaluate the efficacy of imiquimod 5% cream to treat biopsy proven squamous cell carcinoma in situ and they achieved 73% of resolution with no relapse during the 9-month follow-up period. Although imiquimod is not approved by the US Food and Drug Administration for the treatment of periocular lesions due to the potential risk of contact with the globe, Brannan et al [7 ] described a patient who was cured after completing a 3-month treatment; the lesion disappeared and no recurrence was noted 6 months postoperatively, but the patient developed a cicatricial lower-lid ectropion that required correction with a skin graft. Although imiquimod seems to be effective for the treatment of Bowen's disease, its use in the periocular area is still controversial.…”

Section: Bowen's Diseasementioning

confidence: 96%

Management of malignant and benign eyelid lesions

Bernardini¹

2006

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Bowen's Diseasementioning

confidence: 96%

Management of malignant and benign eyelid lesions

Bernardini¹

2006

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…also reported cicatricial ectropion after the treatment of Bowen disease with IMQ and the patient underwent surgery for repair of ectropion. [13] We did not observe cicatricial ectropion requiring surgery in our patients.…”

Section: Discussionmentioning

confidence: 52%

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Karabulut¹,

Kaynak²,

Öztürker³

et al. 2017

Indian J Ophthalmol

View full text Add to dashboard Cite

Context (Background):Imiquimod (IMQ) 5% cream is an immunomodulatory and antitumorigenic agent, which was used as a topical treatment regimen, who had periocular basal cell carcinoma (BCC).Aim:This study aims to present three cases with large BCC at the medial canthal area treated with IMQ 5% cream.Materials and Methods:IMQ 5% cream was used in three patients with ages 45, 49, and 73 who preferred medical treatment over surgery. Following incisional biopsy IMQ cream was used once a day, 5 times a week and the patients were followed up weekly during 12 week treatment period and monthly after the clearance of the lesion.Results:Erythema and erosion on the surface of the lesion, injection of conjunctiva, burning and itching sensation, epiphora and punctate keratitis were seen in all patients during the treatment period. The ophthalmic side effects could be managed by topical lubricating eye drops and the inflammatory reactions resolved within 1 month after cessation of therapy. The patients were followed up for at least 3 years without tumor recurrence and the biopsies taken from the suspected area were found to be tumor free.Conclusion:Surgical excision of carcinoma of the eyelid at medial canthal area can be difficult without causing damage to the lacrimal system and reconstruction of the defect may need grafts or flaps. IMQ may provide an alternative therapy to surgery in certain cases.

show abstract

“…Concurrent artificial drops, as reported by Blasi et al, were also prescribed for the patient (6). Brannan et al suggested that reducing dosing regimen might reduce side effects (17). Local inflammatory reaction noted in our patient was acceptable in treatment of premalignant condition.…”

Section: Resultsmentioning

confidence: 64%

Imiquimod 5% Cream for The Treatment of Actinic Keratosis of The Eyelid

Karabulut¹

2017

Beyoglu Eye J

View full text Add to dashboard Cite

A 61-year-old male presented with 20 x 15 mm diffuse, hyperpigmented lesion that covered the right upper eyelid and which had been present for 2 years. Lesion was diagnosed as actinic keratosis (AK). Since the patient refused surgery and reconstruction, he was treated with imiquimod (IMQ) 5% cream once a day, 5 times per week for 6 weeks. Lesion gradually reduced in size and no clinically evident residual keratosis was observed after treatment. No post-therapy excision was performed to assess histological clearance of AK for cosmetic reasons. Although surgery is first-line treatment for these lesions, in case of refusal to undergo surgery, when lesion is superficial and diffuse and in region where reconstruction would be difficult, treatment with IMQ may be preferred.

show abstract

Bowen Disease of the Eyelid Successfully Treated with Imiquimod

Cited by 31 publications

References 5 publications

Management of malignant and benign eyelid lesions

Management of malignant and benign eyelid lesions

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Imiquimod 5% Cream for The Treatment of Actinic Keratosis of The Eyelid

Contact Info

Product

Resources

About